All In Biotech

Drug Trial Radar · NCT03539601

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

A PHASE 3B/4, MULTICENTER, RANDOMIZED, ASSESSOR BLINDED, VEHICLE AND ACTIVE (TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR) CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY, SAFETY, AND LOCAL TOLERABILITY OF CRISABOROLE OINTMENT, 2% IN PEDIATRIC AND ADULT SUBJECTS (AGES 2 YEARS AND OLDER) WITH MILD TO MODERATE ATOPIC DERMATITIS

Last checked: Nov 20, 2026Latest source record: Jan 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 237 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

237

Actual

Start

Apr 27, 2018

Primary completion

Dec 11, 2020

Study completion Dec 11, 2020

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
May 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This 4-week study will evaluate the safety and efficacy of crisaborole ointment 2%; crisaborole vehicle; topical corticosteroid and topical calcineurin inhibitor, applied twice daily (BID) in subjects who are at least 2 years of age with mild-moderate AD. A Sub-Study of Optical Coherence Tomography and Biomarkers in Subjects ages 2 to \<18 years old, with Mild to Moderate Atopic Dermatitis, treated with Crisaborole Ointment, 2% or Crisaborole Vehicle Ointment or Hydrocortisone Butyrate 0.1% Cream applied BID will also be conducted at select sites.

Conditions

  • Atopic Dermatitis

Interventions

  • Crisaborole ointment, 2%Drug

    Applied twice a day (BID)

  • Hydrocortisone butyrate cream, 0.1%Drug

    Applied BID

  • Pimecrolimus cream, 1%Drug

    Applied BID

  • Crisaborole VehicleDrug

    Applied BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in the Eczema Area and Severity Index (EASI) Total Score at Day 29Time frame: Baseline, Day 29
  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Discontinuations Due to AEs and SAEsTime frame: From Baseline up to 28 days after last dose of study treatment (maximum up to 60 Days)
  3. Number of Participants With Local Tolerability Adverse Events (AEs)Time frame: From Baseline up to 28 days after last dose of study treatment (maximum up to 60 Days)
  4. Number of Participants With Clinically Significant Changes in Vital SignsTime frame: Screening up to Day 29
  5. Number of Participants With Clinically Significant Abnormal Laboratory ParametersTime frame: Screening up to Day 29

Locations

32 sites in 7 countries. Site status is shown where the registry gives one.

  • Dermatology Trial Associates

    Bryant, Arkansas

  • California Dermatology & Clinical Research Institute

    Encinitas, California

  • Park Avenue Dermatology

    Orange Park, Florida

  • Lenus Research & Medical Group, LLC

    Sweetwater, Florida

  • ForCare Clinical Research

    Tampa, Florida

  • DS Research

    Louisville, Kentucky

  • M3-Wake Research, Inc.

    Raleigh, North Carolina

  • Arlington Research Center, Inc.

    Arlington, Texas

  • Tanner Clinic

    Layton, Utah

  • Virginia Clinical Research, Inc

    Norfolk, Virginia

  • ISA - Interdisciplinary Study Association GmbH

    Berlin, Germany

  • Universitaetsklinikum Frankfurt

    Frankfurt am Main, Germany

  • Klinikum der Universitat Munchen

    München, Bavaria, Germany

  • Fachklinik Bad Bentheim, Fachbereich Dermatologie und Allergologie, Dermatologische Ambulanz

    Bad Bentheim, Lower Saxony, Germany

  • Universitatsklinikum Bonn

    Bonn, North Rhine-Westphalia, Germany

  • Universitatsklinikum Schleswig-Holstein, Campus Lubeck

    Lübeck, Schleswig-Holstein, Germany

  • UOSD Dermatologia Gen. ed Oncologica DU, PO San Salvatore

    L’Aquila, AQ, Italy

  • DiSSal Sezione di Dermatologia Az. Ospedaliera Universitaria

    Genova, GE, Italy

  • Ospedale San Pietro Fatebenefratelli

    Roma, RM, Italy

  • Azienda Ospedaliero - Universitaria Policlinico Tor Vergata

    Roma, ROME, Italy

  • Silmedic sp. z o.o

    Katowice, Poland

  • Krakowskie Centrum Medyczne sp. z o.o.

    Krakow, Poland

  • Klinika Ambroziak Sp. z O. O.

    Warsaw, Poland

  • ROYALDERM Agnieszka Nawrocka

    Warsaw, Poland

  • Barbara Rewerska Diamond Clinic

    Krakow, Malopolska, Poland

  • Barn och Ungdomskliniken

    Örebro, Sweden

  • Avdelningen for Kliniska Provningar

    Örebro, Sweden

  • Universitatsklinik fuer Dermatologie

    Bern, Switzerland

  • Centre Hospitalier Universitaire Vaudois (CHUV)

    Lausanne, Switzerland

  • Universitats-Kinderspital Zurich

    Zurich, Switzerland

  • Rame Medical Ltd, Penntorr Health

    Torpoint, Cornwall, United Kingdom

  • NHS Tayside, Ninewells Hospital and Medical School

    Dundee, Scotland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.